Clinical Pharmacogenetics Implementation Consortium (CPIC)

临床药物遗传学实施联盟 (CPIC)

• 批准号: 9789347
• 负责人: Kelly E. Caudle
• 金额: $ 98.14万
• 依托单位: ST. JUDE CHILDREN'S RESEARCH HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-09-20 至 2023-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9789347
• 关键词: Address; Adopted; Affect; Alleles; Area; Authorship; Clinic; Clinical; Clinical Medicine; Clinical Pharmacology; Clinical Practice Guideline; Communities; Conflict (Psychology); Consensus; Data; Databases; Ensure; Funding; Gene Frequency; Genes; Genetic; Genetic screening method; Genomic medicine; Genomics; Goals; Grouping; Guidelines; Hospitals; Individual; Industry; Institute of Medicine (U.S.); Institution; International; Journals; Knowledge; Laboratories; Language; Level of Evidence; Link; Medical Genetics; Monoclonal Antibody R24; Nomenclature; Patient Care; Peer Review; Pharmaceutical Preparations; Pharmacogenetics; Pharmacogenomics; Phenotype; Plant Roots; Poaceae; Process; PubMed; Publishing; Recommendation; Research; Research Personnel; Resources; Solid; Standardization; Support Groups; System; Terminology; Test Result; Therapeutic; Time; Translating; Translations; United States National Institutes of Health; Update; Variant; Work; Writing; base; clinical decision support; clinical implementation; clinical practice; clinically actionable; data resource; disorder risk; evidence base; evidence based guidelines; genetic variant; genomic data; genomic variation; health record; implementation research; improved; indexing; novel therapeutics; outreach; pharmacogenetic testing; precision medicine; tool; uptake; volunteer

ABSTRACT Pharmacogenomics is often cited as the subset of genomic research that is most amenable to uptake in clinical medicine. Over the last few years, leading institutions have begun using pharmacogenetic test results to guide prescribing in some clinical settings, but clinical implementation efforts have documented that rigorous guidelines are needed to optimally use pharmacogenetic test results. Recognizing this need, we formed the Clinical Pharmacogenetics Implementation Consortium (CPIC®) in 2009. The goal of CPIC is to provide resources needed to translate raw genetic test information into prescribing recommendations for specific gene/drug pairs. This is accomplished through the creation, curation, and dissemination of peer-reviewed, evidence-based, freely available clinical practice gene/drug guidelines. CPIC is the only NIH-supported group to focus on translation of pharmacogenomic variation into prescribing actions. We have two specific aims: Aim 1 is to create, curate, and update pharmacogenetic guidelines, and Aim 2 is to work with guideline users and other public genomic resources to coordinate efforts, disseminate CPIC content, and be responsive to the needs of the global genomics community. CPIC guidelines are published after standard peer review, and are simultaneously posted online allowing for real-time updates of guidelines as new information emerges. CPIC assigns gene/drug pairs to levels of actionability based on standardized criteria. CPIC investigators, working with internationally recognized experts in each content area, write clinical guidelines for those genes that are clearly actionable for at least one drug. Guidelines follow best practices, using a standardized format, grading for levels of evidence and strength of clinical recommendations, and adhering to authorship processes that are consistent with the Institute of Medicine best practices for clinical guidelines. Guidelines include tables of the genomic variants that define alleles, assign function to alleles, estimate allele frequency among major ancestry groups, translate diplotypes into phenotypes, provide prescribing actionability for phenotypes, and include example clinical decision support language. Considerable outreach efforts by CPIC will continue and have resulted in broad uptake and endorsement of CPIC guidelines. Content is organized to facilitate usage by the broad research and clinical community, including related public databases such as PharmGKB, ClinGen, ClinVar, and PharmVar.

摘要 药物基因组学通常被认为是基因组研究的子集，最适合于临床应用。 药在过去的几年里，领先的机构已经开始使用药物遗传学测试结果来指导 在一些临床环境中处方，但临床实施工作已经记录了严格的 需要指导方针来最佳地使用药物遗传学测试结果。认识到这一需要，我们成立了 2009年，临床药物遗传学实施联盟（CPIC®）。CPIC的目标是提供 将原始基因检测信息转化为特定的处方建议所需的资源 基因/药物配对。这是通过创建，策展和传播同行评审， 基于证据的，免费提供的临床实践基因/药物指南。CPIC是NIH支持的唯一一个 专注于将药物基因组学变异转化为处方行为。我们有两个具体目标： 1是创建，策划和更新药物遗传学指南，目标2是与指南用户合作， 其他公共基因组资源，以协调工作，传播CPIC内容，并响应 满足全球基因组学界的需求。CPIC指南在标准同行评审后发布， 同时在线发布，以便在出现新信息时实时更新准则。太保 基于标准化的标准将基因/药物对分配到可作用的水平。CPIC调查员， 与国际公认的专家在每个内容领域，为那些基因， 至少对一种药物有明确的可诉性。指南遵循最佳实践，使用标准化格式，分级 临床建议的证据水平和强度，并遵守作者身份流程， 符合医学研究所临床指南的最佳实践。准则包括 定义等位基因的基因组变异，分配等位基因的功能，估计主要祖先中的等位基因频率 组，将二倍体型翻译成表型，提供表型的处方活性，并包括 示例临床决策支持语言。CPIC将继续开展大量外联工作， 导致CPIC准则得到广泛采纳和认可。组织内容以方便 广泛的研究和临床社区，包括相关的公共数据库，如PharmGKB，ClinGen， ClinVar和PharmVar。